Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Teva CEO Levin Steps Down

By Drug Discovery Trends Editor | October 30, 2013

(Source: Teva)Shares of Teva Pharmaceutical Industries Ltd. sank in premarket trading today after the drugmaker said President and CEO Jeremy Levin has agreed to resign less than two years into the job.
 
The Israeli company said its board and Levin agreed that he will step down. The board named Chief Financial Officer Eyal Desheh an interim replacement and formed a committee to start searching for a permanent successor.
 
Teva, which reports third-quarter results on Thursday, gave no reason for the resignation in a Wednesday morning statement.
 
Levin is a former senior executive at U.S. drugmaker Bristol-Myers Squibb who became CEO in 2012 after Shlomo Yani stepped down.
 
Teva is one of the world’s largest generic drugmakers. It has struggled in recent quarters with declining sales for both generic and brand-name drugs.
 
The drugmaker announced a restructuring in 2012 and said earlier this month that it planned to cut 5,000 employees, or about 10 percent of the global workforce, by the end of next year. The restructuring aims to slim the drugmaker’s business and make it more efficient.
 
The company took heavy criticism for the cuts in its home country, where it is affectionately known as “Israel’s company.” Political leaders noted that Teva is making these cuts while also enjoying sweeping tax exemptions.
 
Date: October 30, 2013
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50